Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
SynKinase
Selumetinib
Product Details | |
---|---|
Synonyms | AZD6244; ARRY-142886 |
Product Type | Chemical |
Properties | |
Formula | C17H15BrClFN4O3 |
MW | 457.7 |
CAS | 606143-52-6 |
Purity Chemicals | ≥95% |
Appearance | Solid. |
Solubility | Soluble in DMSO. Slightly soluble (<1mg/ml) in ethanol. |
Declaration | Manufactured by SynKinase. |
Other Product Data |
Target: mTOR | Kinase Group: Atypical (PIKK) | Substrate: Serine-Threonine Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet. |
InChi Key | CYOHGALHFOKKQC-UHFFFAOYSA-N |
Shipping and Handling | |
Shipping | AMBIENT |
Short Term Storage | +4°C |
Long Term Storage | -20°C |
Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
Documents | |
MSDS | Download PDF |
Product Specification Sheet | |
Datasheet | Download PDF |
Selumetinib (AZD6244) is a second-generation, orally available, potent and selective ATP non-competitive inhibitor of MEK 1/2. In direct assays, AZD6244 selectively inhibits purified active MEK1 and MEK2 with an IC(50) of 14nM, and AZD6244 has reported IC(50) values of < 100nm for MEK1 in ELISA assays and in bindings assays against recombinant domains of MEK2, Kd values were 53nM for AZD6244. AZD6244 demonstrated very effective anti-proliferation effects against several different cell lines with IC(50) values ranging from a low of 3nM to < 1µM depending upon the cell system used, and the compound inhibits basal and growth factor-stimulated phosphorylation of ERK1/ 2 with IC(50) concentrations < 40nM. AZD6244 has demonstrated potent dose-dependent antitumor activity against a panel of mouse xenograft models of colorectal, pancreatic, liver, skin, and lung cancer, and inhibition of tumor growth was found to correlate with the reduction of phospho-ERK1/2 levels in tumors.
- Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor: T.C. Yeh, et al.; Clin. Cancer. Res. 13, 1576 (2007)
- Optimization of allosteric MEK inhibitors. Part 1: Venturing into underexplored SAR territories: I.V. Hartung, et al.; Bioorg. Med. Chem. Lett. 23, 2384 (2013)